Review of a promising new agent—pemetrexed disodium
✍ Scribed by Luis Paz-Ares; Susana Bezares; José M. Tabernero; Daniel Castellanos; Hernán Cortes-Funes
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 113 KB
- Volume
- 97
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Pemetrexed disodium (ALIMTa, [pemetrexed], LY231514; Eli Lilly and Company; Indianapolis, IN), a novel antifolate antimetabolite with multiple enzyme targets involved in both pyrimidine and purine synthesis, has entered clinical trials due to its favorable pleclinical profile. Many studies utilizing the drug, as a single or combination agent, are currently ongoing, including Phase III trials in mesothelioma, nonsmall cell lung carcinoma (NSCLC) and pancreatic cancer. Promising feasibility and activity data have been obtained with pemetrexed in combination with platinum compounds and gemcitabine. The supplementation with daily oral folate could reduce the incidence of hematologic toxicities while preserving the antitumor activity of pemetrexed.
📜 SIMILAR VOLUMES
## BACKGROUND. The aim of this study was to confirm the activity and assess the safety profile of multitargeted antifolate (MTA) for patients with metastatic colorectal adenocarcinoma. ## METHODS. Forty-six patients were enrolled in the study, 35 with colon and 11 with rectal carcinoma. Adjuvant
"After having her heart broken by a country music star, Savannah Braden has sworn off men. She takes a break from her fast-paced Manhattan lifestyle for a weekend at a survivor camp to rebuild her confidence and readjust her priorities. But when she meets the handsome guide, Jack Remington, she's dr
## Abstract Epidemiological and preclinical evidence suggests that polyphenolic phytochemicals exemplified by epigallocatechin gallate from tea, curcumin from curry and soya isoflavones possess cancer chemopreventive properties. Whilst such naturally occurring polyphenols have been the subject of n
## Abstract ## BACKGROUND. There is a need to identify active new regimens in patients with advanced urothelial cancer. Pemetrexed and gemcitabine are active agents in advanced urothelial cancer. A phase 2 trial of the combination of these 2 agents was performed in patients with advanced urothelia